Physician profile
Robert Marquinez
NPI 1407910714
$3,202.96
in general payments reported to CMS, 2019-2025
25 companies · $987 in 2025
The $987 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $171 · 2021: $239 · 2022: $304 · 2023: $388 · 2024: $594 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,147.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $641.69 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $223.60 | 2022-2025 | |
| Lilly USA, LLC | $194.97 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $138.68 | 2021-2025 | |
| Pfizer INC. | $125.00 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $106.64 | 2019-2021 | |
| Amgen INC. | $103.90 | 2020-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $88.33 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Sanofi-Aventis U.S. LLC | $53.62 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $48.06 | 2019-2022 | |
| Allergan, INC. | $47.87 | 2019 | |
| Livanova USA, INC. | $43.50 | 2019 | |
| Sanofi Pasteur INC. | $40.16 | 2023-2025 | |
| Glaxosmithkline, LLC. | $29.69 | 2024 | Shingrix, Arexvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.32 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $24.30 | 2019 | |
| Exact Sciences Corporation | $17.86 | 2024 | Cologuard Collection Kit |
| Radius Health, INC. | $17.11 | 2020 | |
| Abbott Laboratories | $15.78 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $15.35 | 2023 | Austedo Xr |
| Dexcom, INC. | $14.47 | 2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $14.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.51 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marquinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.